Pfizer Saudi Limited signed an exclusive commercial agreement with Tabuk Pharmaceuticals. The deal will permit Pfizer to advertise and promote branded and high-value generic drugs, such as medicines that provide treatment for kidney dialysis, kidney transplant, urology, and the central nervous system. This agreement is part of a larger Vision 2030 effort to strengthen local manufacturing capabilities. Pfizer started production at a $50 million plant in Saudi Arabia in January.
Pfizer Signs Commercial Agreement
You also might be interested in
April 23-25, 2018 Riyadh and Dhahran U.S. Commercial Nuclear Mission[...]
On March 11, 2014, the U.S.-Saudi Arabian Business Council (USSABC)[...]
The Fitch Ratings Agency has maintained its A+ on Saudi[...]